HWPC(SH:688799)2023-12-27 09:16Group 1: Company Overview - Warner Pharmaceutical has 54 specialized chemical raw materials, with 41 products having an "A" registration status [2] - The company aims to enhance market share of its advantageous raw materials by integrating related services and strategic ordering with domestic generic drug companies [2] - In 2022, revenue from raw materials and intermediates reached CNY 207 million, with a revenue of CNY 220 million in the first three quarters of 2023 [2] Group 2: Research and Development - ZG-001, an innovative Class 1 drug under development, has received clinical trial approval and targets treatment for Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD) [2] - The company is collaborating on artificial substitutes for rare and endangered animal medicines, utilizing its established production systems for research and development [3] Group 3: Product Information - Sodium Docusate Tablets are the only formulation of its kind in China, used for treating chronic functional constipation with a gentle and safe mechanism [3] - Montmorillonite Powder, a classic treatment for diarrhea, holds a market share of 42.40% in public hospitals and community health centers as of 2022 [3][4] - The company’s new product, Levosalbutamol Hydrochloride Nebulization Solution, was approved in October 2023 and is indicated for reversible airway obstruction in adults and children over 6 years old [4] - Bromovirin Tablets, approved in April 2023, are used for early treatment of acute herpes zoster in immunocompetent adults, demonstrating high selectivity in antiviral action [4]